This pre-clinical study demonstrated that this influenza subunit vaccine produced higher antibody titres (IgG2a and IgA) and increased the percentage of antigen-associated phagocytes in the nasal mucus layer, leading to strong humoral protection against influenza challenge with A/New Caledonia/20/1999 (H1N1) influenza virus, when compared with the influenza antigen alone [197]. The gene discussed is CD79A; the disease is influenza.